QNTM
Quantum Biopharma Ltd.
$4.26
-4.91%
$27.3M
No data for this timeframe.
Vol
Market Cap$27.3M
Cap SizeNano Cap
Inst. Holders2 funds
Inst. Value$1.8K
Inst. Activity0 buys / 2 sells
SEC Reports9
Press Releases6
Recent Activity
Jun 2, 2026
SEC
Quantum BioPharma disclosed that the FDA placed its lead drug candidate Lucid-MS (for multiple sclerosis) on clinical ho
6-K — Impact 7/10
Jun 2, 2026
SEC
Quantum BioPharma engaged Stocks.news/IR Agency LLC for investor relations and marketing services for 6 months at a $250
6-K — Impact 3/10
May 18, 2026
SEC
Quantum BioPharma announced that its collaborative imaging study with Massachusetts General Hospital has reached the mid
6-K — Impact 6/10
Inst.
MORGAN STANLEY — NEAR_EXIT
243 shares ($1.8K)
Inst.
BANK OF AMERICA CORP — NEAR_EXIT
4 shares ($29.00)
Jun 2, 2026
other
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
<p align="justify">TORONTO, June 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM
Apr 22, 2026
Press
Quantum BioPharma announced the appointment of Richard Buzbuzian as CEO of Unbuzzd Wellness Inc., its majority-owned con
Impact 4/10
Apr 1, 2026
Press
Quantum BioPharma (QNTM) announced the submission of an Investigational New Drug (IND) application to the FDA for Lucid-
Impact 6/10
Price Targets
No recent covering-analyst activity on file. No current recommendation available.
$12.52
Current $4.26
Low $12.52
Median $12.52
High $12.52
1 analysts
$12.52
$12.52
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.59 | $-0.59 — $-0.59 | 1 | |
| Next Q | $-0.70 | $-0.70 — $-0.70 | 61% YoY | 1 |
| Current FY | $-2.58 | $-2.58 — $-2.58 | 77% YoY | 1 |
Latest Reports
BEARISH
6-K
7/10
Quantum BioPharma disclosed that the FDA placed its lead drug candidate Lucid-MS (for multiple sclerosis) on clinical ho
Jun 2, 2026
NEUTRAL
6-K
3/10
Quantum BioPharma engaged Stocks.news/IR Agency LLC for investor relations and marketing services for 6 months at a $250
Jun 2, 2026
NEUTRAL
Press
4/10
Quantum BioPharma announced the appointment of Richard Buzbuzian as CEO of Unbuzzd Wellness Inc., its majority-owned con
Apr 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $1.8K | NEAR_EXIT |
| BANK OF AMERICA CORP | $29.00 | NEAR_EXIT |
2 institutional holders with $1.8K total value (247 shares) as of 2025-Q4. Top holders: MORGAN, BANK. Net selling activity: 2 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 243 | $1.8K | 98.4% | NEAR_EXIT -90.5% |
| 2 | BANK OF AMERICA CORP /DE/ | 4 | $29.00 | 1.6% | NEAR_EXIT -96.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | NEAR_EXIT | 2,564 | 243 | -90.5% | $1.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 100 | 4 | -96.0% | $29.00 | 2025-Q4 |
| UBS Group AG | NEAR_EXIT | 45,883 | 8,754 | -80.9% | $143.6K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 131 | 2,564 | +1857.3% | $42.0K | 2025-Q3 |
| UBS Group AG | DOUBLED | 1,614 | 45,883 | +2742.8% | $929.1K | 2025-Q2 |
| MORGAN STANLEY | NEAR_EXIT | 2,532 | 131 | -94.8% | $2.7K | 2025-Q2 |
| MORGAN STANLEY | NEW | — | 2,532 | — | $19.5K | 2025-Q1 |
| UBS Group AG | NEW | — | 1,614 | — | $12.4K | 2025-Q1 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
9 SEC filing reports analyzed. Sentiment: 4 bullish, 1 bearish, 0 mixed, 4 neutral. Avg impact: 5.4/10.
BEARISH
6-K
7/10
Quantum BioPharma disclosed that the FDA placed its lead drug candidate Lucid-MS (for multiple scler
Jun 2, 2026
NEUTRAL
6-K
3/10
Quantum BioPharma engaged Stocks.news/IR Agency LLC for investor relations and marketing services fo
Jun 2, 2026
BULLISH
6-K
6/10
Quantum BioPharma announced that its collaborative imaging study with Massachusetts General Hospital
May 18, 2026
NEUTRAL
6-K
4/10
Quantum Biopharma Ltd. announced the appointment of Richard Buzbuzian as CEO of Unbuzzd Wellness Inc
Apr 22, 2026
BULLISH
6-K
7/10
Quantum Biopharma announced a legal victory as a U.S. District Court denied the joint motion to dism
Apr 2, 2026
BULLISH
6-K
7/10
Quantum Biopharma Ltd. (QNTM) announced the submission of an Investigational New Drug (IND) applicat
Apr 1, 2026
NEUTRAL
COURT-RULING
3/10
Analysis based on filing metadata only — document content was unavailable
Mar 30, 2026
BULLISH
6-K
8/10
Quantum Biopharma reported its 2025 audited financial results, showing improved financial health wit
Mar 27, 2026
NEUTRAL
6-K
4/10
Quantum Biopharma Ltd. announced the appointment of Dr. Salvatore Napoli as Principal Investigator f
Mar 26, 2026
NEUTRAL
4/10
Quantum BioPharma announced the appointment of Richard Buzbuzian as CEO of Unbuzzd Wellness Inc., it
Apr 22, 2026
MIXED
6/10
Quantum BioPharma (QNTM) announced the submission of an Investigational New Drug (IND) application t
Apr 1, 2026
MIXED
6/10
Quantum BioPharma reported its 2025 financial results, highlighting a reduction in operating expense
Mar 27, 2026
BULLISH
7/10
Quantum BioPharma announced the peer-reviewed publication of a clinical trial showing its dietary su
Mar 23, 2026
NEUTRAL
5/10
Quantum BioPharma has closed the first tranche of its offering, raising $3.75 million through the is
Mar 20, 2026
NEUTRAL
4/10
Quantum BioPharma (QNTM) announced it will release its Q4 and full-year 2025 financial results on Ma
Mar 10, 2026
Historical analyst distribution: 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
No recent covering-analyst activity on file. No current recommendation available.
$12.52 mean target
$12.52 Low
$12.52 High
| Metric | Value |
|---|---|
| Current Price | $4.26 |
| Target Low | $12.52 |
| Target Mean | $12.52 |
| Target Median | $12.52 |
| Target High | $12.52 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.59 | $-0.59 | $-0.59 | — | — | 1↑ 0↓ | $0.0B | — | 1 |
| Next Q 2026-09-30 |
$-0.70 | $-0.70 | $-0.70 | 60.5% | — | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-2.58 | $-2.58 | $-2.58 | 77.3% | — | — | $0.0B | — | 1 |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.586 | |
| 7d ago | $0.000 | -0.586 |
| 30d ago | $0.000 | -0.586 |
| 60d ago | $0.000 | -0.586 |
| 90d ago | $0.000 | -0.586 |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
other
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
<p align="justify">TORONTO, June 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum</stron
Jun 1, 2026
other
Quantum BioPharma Provides Corporate Update
<p>THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINAT
May 26, 2026
short_volume
Short Volume: QNTM — 59.0% short (0.5M / 0.8M)
Short: 461,500 | Exempt: 22,847 | TRF Vol: 781,646 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
May 21, 2026
Clinical Trial
Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
Phase Phase 2 — TERMINATED
May 18, 2026
other
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
Promising Early Data Strengthens Potential of Novel PET Technology to Advance Development of Lucid-MS for Multiple Sclerosis <pre> Promising Early Dat
May 7, 2026
earnings
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
Investigational New Drug (IND) Application Filed to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple
Apr 27, 2026
other
Quantum BioPharma Provides Corporate Update
<p align="justify">THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVIC
Apr 27, 2026
short_volume
Short Volume: QNTM — 57.7% short (0.6M / 1.1M)
Short: 649,393 | Exempt: 8,020 | TRF Vol: 1,125,420 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
fda
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
<p align="justify">TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum BioPh
Apr 21, 2026
short_volume
Short Volume: QNTM — 58.1% short (0.3M / 0.6M)
Short: 345,164 | Exempt: 1,044 | TRF Vol: 594,381 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
other
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
<p align="justify">TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum BioPh
Apr 1, 2026
regulatory
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
<p align="justify">TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum BioPh
Mar 30, 2026
fda
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
Strategic Partnership with Global Clinical Research Organization (CRO) Signifies Advancement in Clinical Development of Lucid-21-302 (Lucid-MS), a Nov
Mar 30, 2026
short_volume
Short Volume: QNTM — 57.2% short (0.7M / 1.3M)
Short: 719,335 | Exempt: 31,790 | TRF Vol: 1,257,692 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
Enforcement
1:24-cv-07972 Quantum BioPharma Ltd. v. CIBC World Markets, Inc et al
Court ruling from United States District Court for the Southern District of New York. Docket: N/A
Mar 27, 2026
other
Quantum Biopharma Provides Corporate Update
<p align="center">THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICE
Mar 27, 2026
earnings
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status
Financial Statements as of Date of Filing Show Strong Improvements in Cash, Reduction in Accounts Payable, and a Cash Runway Through January 2028 <pre